

This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Melanoma	Wingless-type MMTV integration site family member 3A (WNT3A); BRAF	<p>Mouse studies suggest activating WNT signaling may increase the efficacy of BRAF inhibitors in melanoma. In a xenograft mouse model of melanoma, a BRAF inhibitor plus transplantation of cells overexpressing WNT3A led to less tumor growth than a BRAF inhibitor plus transplantation of cells expressing a control protein.</p> <p>Zelboraf vemurafenib, a BRAF inhibitor from Daiichi Sankyo Co. Ltd. and Roche, is marketed to treat metastatic melanoma.</p> <p>SciBX 5(5); doi:10.1038/scibx.2012.121 Published online Feb. 2, 2012</p>	Patent applications filed; available for licensing	<p>Biechele, T.L. <i>et al. Sci. Signal.</i>; published online Jan. 10, 2012; doi:10.1126/scisignal.2002274</p> <p>Contact: Andy J. Chien, University of Washington School of Medicine, Seattle, Wash. e-mail: andchien@uw.edu</p> <p>Contact: Randall T. Moon, same affiliation as above e-mail: rtmoon@uw.edu</p>